Subject: PSID Video Chart with Tech Analysis

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
PSID Video Chart with Tech Analysis
Hot Stock to WatchHot Stock to Watch

Company: PositiveID Corporation (OTCQB: PSID)


Price: 0.0157

Change (%): + 0.0002 (1.29)

Volume: 932,667
PSID Chart

See New Video Chart

Video Chart

PositiveID Corp. and GenArraytion, Inc. Join Forces as the Threat of Zika Continues to Rise

Feb. 2, 2016 PositiveID Corp. (OTCQB:PSID) has partnered with GenArraytion, Inc. who recently announced the development of the first commercially available polymerase chain reaction (PCR)-based molecular test to identify the Zika virus, a fever-causing disease transmitted by the Aedes aegypti mosquito. The Zika virus test works with an existing GenArraytion MultiFLEX™ Bioassay panel that targets viruses that cause dengue fever, yellow fever and Chikungunya, which are also carried by this mosquito and are known to cause febrile disease in humans. The Aedes Aegypti MultiFLEX™Bioassay test is designed to work on bead-based endpoint instruments and real-time PCR platforms, such as Positive ID’s, Firefly DX. The test targets four genetic regions of the Zika virus, making detection possible even if the virus mutates in the future. MultiFLEX™ molecular assays help health officials identify infectious diseases in panels with up to 20 genetic markers, for fever-causing and vector-borne disease organisms of concern.

PositiveID’s Firefly Dx is a hand-held unit designed to analyze biological samples and deliver molecular diagnostic results in less than 30 minutes. The portable nature of the Firefly Dx enables health care officials working in the field to accurately test and diagnose individuals on-the-spot. The rapid response of the Firefly Dx could allow officials to quickly assess a population’s exposure and enact measures to contain and prevent further spread of the infectious disease. To date, Firefly has demonstrated the ability to detect and identify many pathogens and diseases including, Ebola, measles, seasonal and avian flu, E. coli, and methicillin-resistant staphylococcus aureus (“MRSA”). With the use of GenArrayation Inc.’s assays in the future, Firefly Dx may also detect Zika, dengue fever, yellow fever, and Chikungunya.

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks